{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-009380","form_type":"8-K","ticker":"LFMD","cik":"0000948320","company_name":"LifeMD, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.097953+00:00","generated_at":"2026-05-15T18:29:11.856989+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LifeMD FY2025 rev $194.1M (+25%), adj EBITDA $15.3M (+309%); guides to >$250M run-rate by Q4 2026","bullets":["FY2025 revenue $194.1M (+25% YoY); adjusted EBITDA $15.3M (+309% YoY).","Q4 2025 revenue $46.9M (+4% YoY); adjusted EBITDA $4.8M (+348% YoY).","Launched oral Wegovy post-year-end; >80% of new weight management patients using branded therapy; Q1 sign-ups at record levels.","Ended 2025 with $36.8M cash, no debt; guides to annualized revenue >$250M and adj EBITDA >$25M by Q4 2026.","Benefits infrastructure on track to cover ~220M Americans in Q2 2026; women's health seeing strong early growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-009380","json":"https://secwatch.observer/filing/0001493152-26-009380.json","markdown":"https://secwatch.observer/filing/0001493152-26-009380.md","text":"https://secwatch.observer/filing/0001493152-26-009380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/948320/000149315226009380/0001493152-26-009380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/948320/000149315226009380/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:29:11.856989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}